Marc Beer has more than 25 years of commercialization and development experience in the field of pharmaceuticals, devices, biotechnology, and diagnostics. He founded Renovia Company together with Ramon Iglesias, Yolanda Lorie and MD in the year 2016. The company successfully closed its series of financing with the topmost healthcare venture funds. In the year 200, Mark Beer became the Chief Executive Officer of the ViaCell. The company is a biotechnology firm that specializes in the development, preservation and the collection of the umbilical cord blood stem cell.
For the past seven years, he has led the firm from its inception to a robust and rapidly growing commercial company. Under his leadership as the CEO, the organization went public in the year 2005 and grew with over 300 employees. In addition to serving as the Chief Executive Officer of the company, he also served as a member of the biopharmaceutical organization and the board of directors of the Erytech Pharma.
Marc Beer is a graduate of Miami University, Oxford, OH. In his career, he held various career positions within a specialty care firm that is committed to improving treatments of the debilitating body issues that are difficult to treat and diagnose. The most recent position that he has held is the deputy president of the Global Marketing where Marc Beer was responsible for the launch of various firm products. Its main objective was to address the rare disease populations on the world scale. He was also the founding Chairperson of the board of directors and the compensation board of Good Start Genetics.
Marc Beer’s Support for the Women Health Startup
Marc Beer recently raised approximately $42M to fund and support the women’s startup Renovia Inc. The organization offers therapeutic and diagnostic devices for the treatment of various pelvic floor disorders. This funding will help in the development and the testing of four major new products. The organization is developing multiple therapeutic and diagnostic products to treat diseases such as urinary incontinence that will help over 250 million women in the world.
The Longwood support which is a healthcare-centered investment firm that had earlier invested in Renovia, collaborated with the Series B Round to develop and test for diagnostic products which include the current generation of the Leva product. During the funding, Mark Beer said that the organization is excited to have the full support of the company financiers of the organization. He also said that the investors are willing to share the vision of the organization to treat, diagnose and improve the lives of millions of women in the world. Learn more : https://www.slideshare.net/MarcBeer